XOMA LTD. 8K - 11/02/06
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of
Report (Date of Earliest Event Reported): November 2, 2006
XOMA
LTD.
(Exact
name of registrant as specified in its charter)
BERMUDA
(State
or
other jurisdiction of incorporation)
(Former
name or former address, if changed since last report)
|
0-14710
|
52-2154066
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
2910
Seventh Street, Berkeley, California
|
94710
|
|
(Address
of principal executive offices)
|
(Zip
code)
|
|
Registrant's
telephone number, including area code
|
(510)
204-7200
|
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
1.01.
Entry
into a Material Definitive Agreement
As
announced on November 2, 2006, XOMA has announced the formation of a
collaboration with Takeda Pharmaceutical Company Limited, for therapeutic
monoclonal antibody discovery and development. Under the agreement, Takeda
will
make up-front and milestone payments to XOMA, fund XOMA’s R&D activities
including manufacturing of the antibodies for preclinical and early clinical
supplies, and pay royalties to XOMA on sales of products resulting from the
collaboration.
A
copy of
the press release is attached hereto as Exhibit 1
and is
incorporated herein by reference.
Item
9.01.
Exhibits
1. Press
Release dated November 2, 2006.
EXHIBIT
INDEX
Number Description
1. Press
Release dated November 2, 2006.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated:
November 2, 2006 XOMA
LTD.
By:
/s/ Christopher
J. Margolin
Christopher
J. Margolin
Vice
President, General
Counsel
and Secretary